Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q3 2022 Earnings Presentation

39 slides from Walgreens Boots Alliance's earnings presentation, Jun 30, 2022

  1. Slide 1: Fiscal 2022 Third Quarter Results

    Fiscal 2022 Third Quarter Results June 30, 2022 © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 1

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: Takeaways

    Takeaways • Resilient Core Business • Execution across operating segments • Deep community connections and consumer relevance • Lapping strong year-ago quarter including peak COVID-19 vaccination volumes • Building Our Next Growth Engine: Walgreens Health • New strategic partnership with Buckeye Hea

  4. Slide 4: To Be the Leading Partner in Reimagining Local Healthcare and Wellbeing for All

    To Be the Leading Partner in Reimagining Local Healthcare and Wellbeing for All Strategic Priorities: 1. Transform and Align the Core 2. Build Our Next Growth Engine with Consumer-Centric Healthcare Solutions 3. Focus the Portfolio; Optimize Capital Allocation 4. Build a High-Performance Culture and

  5. Slide 5: Growing the Core Business

    Growing the Core Business  U.S. retail comparable sales +1.4%, or +2.4% excl. tobacco, with positive comparable store transactions  U.S. digital sales +25% in 3Q, on top of +95% last year, with 2.8 million same-day pick-up orders  Grew myWalgreens members to over 99 million by the end of 3Q, up 1

  6. Slide 6: Resilient Core Business

    Resilient Core Business Well Positioned to Navigate Challenging Macro Conditions  Proactive management through inflationary cost pressures and supply chain headwinds, exemplified by favorable retail margins  Successful inventory management achieving robust in-stock levels  Local presence, relevan

  7. Slide 7: Building a Winning Team

    Building a Winning Team Strengthened Consumer-Focused Leadership with Three New Executives Linh Peters Luke Rauch Bala Visalatha Chief Marketing Officer Chief Merchandising Officer Chief Product Officer © 2022 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on s

  8. Slide 8: Leading the Fight Against COVID-19

    Leading the Fight Against COVID-19 Vaccinations Boosters Rx Tests1 4.7 million 3.8 million 3.9 million administered/completed in Q3 Over 67 million Over 16 million Over 32 million administered/completed program to date 1) PCR tests Note: Statistics to date as of June 26, 2022 © 2022 Walgreens Boots

  9. Slide 9: Executing to Build Our Next Growth Engine

    Executing to Build Our Next Growth Engine 65% Pro Forma Sales Growth for Walgreens Health Segment in 3Q Health Coverage across 22 markets with responsibility for over 1.6 million patients Contract wins with three significant health Announced strategic partnership with systems in 3Q Buckeye Health Pl

  10. Slide 10: WBA Financial Performance

    WBA Financial Performance © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 10

  11. Slide 11: 3Q 2022 Financial Highlights

    3Q 2022 Financial Highlights • Adj. EPS $0.96, -28.9% below prior year in constant Fx • Lapping prior year peak COVID-19 vaccination period • Investments in Walgreens Health driving pro forma sales +65% • Strong performance in U.S. retail, and International (AOI more than doubled vs. prior year) • S

  12. Slide 12: 3Q 2022 Financial Highlights

    3Q 2022 Financial Highlights Reported Fx Constant Fx Continuing operations 3Q22 $ in millions (except EPS) B/(W) vs. 3Q21 B/(W) vs. 3Q21 Sales $32,597 - 4.2% - 2.8% Operating income GAAP - $320 - $1,454 Adjusted $955 - 34.6% - 33.5% Net earnings GAAP $289 - 73.8% Adjusted $834 - 30.2% - 29.1% EPS GA

  13. Slide 13: Year-to-Date FY22 Financial Highlights

    Year-to-Date FY22 Financial Highlights Reported Fx Constant Fx Continuing operations YTD22 $ in millions (except EPS) B/(W) vs. YTD21 B/(W) vs. YTD21 Sales $100,254 + 2.0% + 2.7% Operating income GAAP $2,209 + 54.3% Adjusted $4,389 + 13.1% + 13.7% Net earnings GAAP $4,752 + 190.5% Adjusted $3,667 +

  14. Slide 14: United States – Financials

    United States – Financials $ in millions 3Q22 B/(W) vs. 3Q21 YTD22 B/(W) vs. YTD21 Sales $26,695 - 7.1% $82,394 - 1.0% Adj. gross profit $5,559 - 9.6% $18,414 + 5.1% Adj. SG&A % of sales 17.9% - 1.1%p 17.8% - 0.8%p Adj. operating income $966 - 34.4% $4,243 + 12.0% Adj. operating margin 1 2.9% - 1.7%

  15. Slide 15: United States – Pharmacy

    United States – Pharmacy 3Q 3Q YTD22 YTD22 3Q22 vs. 3Q21 Total Comparable Total Comparable Pharmacy sales - 9.7% + 2.0% - 4.0% + 5.3% Prescriptions - 2.5% - 1.8% + 2.2% + 2.9% • Comparable pharmacy sales +2.0% in the quarter • Comparable scripts -1.8%; excluding immunizations +2.1% ⎯ 4.7 million COV

  16. Slide 16: United States – Retail

    United States – Retail 3Q22 vs. 3Q21 3Q22 YTD22 Total retail sales + 1.0% + 8.4% Comparable retail sales + 1.4% + 8.8% • 3Q comp retail sales +1.4%; excluding tobacco +2.4% ⎯ Strength in Health & Wellness +7.9% led by cough, cold, and flu, and at-home COVID-19 testing; Personal Care +2.6% partly off

  17. Slide 17: International – Financials

    International – Financials Constant Fx Constant Fx Continuing operations 3Q22 B/(W) vs. 3Q21 YTD22 B/(W) vs. YTD21 $ in millions Sales $5,305 + 9.3% $16,686 + 15.7% Adj. gross profit $1,095 + 11.3% $3,508 +14.8% Adj. SG&A % of sales 17.4% + 1.2%p 17.6% + 1.4%p Adj. operating income $174 + 103.3% $56

  18. Slide 18: Boots UK – Financials

    Boots UK – Financials 3Q22 vs. 3Q21 (constant Fx) 3Q22 YTD22 Pharmacy comp. sales -0.4% + 4.0% Retail comp. sales + 24.0% + 20.7% • Pharmacy comparable sales broadly flat as we lap one-time favorable NHS reimbursement in 3Q21 ⎯ Pharmacy services +22% vs. comparable quarter despite reduction in COVID

  19. Slide 19: Walgreens Health – Financials

    Walgreens Health – Financials Health $ in millions 3Q22 B/(W) vs. 3Q21 YTD22 B/(W) vs. YTD21 Sales $596 + $596 $1,173 + $1,173 Adj. gross profit ($21) ($21) $15 + $15 Adj. SG&A ($108) ($91) ($233) ($202) Adj. operating loss ($129) ($112) ($218) ($187) • VillageMD sales of $511M in 3Q, +69% on a pro

  20. Slide 20: Walgreens Health – Key Metrics

    Walgreens Health – Key Metrics Health Current Status CY22 Goal Lives 2.3M 2M Partners (Payor/Provider) 3 5 Sites of Care: Health Corners 56 100 VillageMD Co-Located Clinics 120 200 Total VillageMD Clinics 315 3Q22 FY22 Goal Sales (Reported) $1.2B YTD $2.0B 3Q22 YTD22 Pro Forma Sales Growth YOY: Vill

  21. Slide 21: Cash Flow

    Cash Flow B/(W) $ in millions YTD22 vs. YTD21 Operating cash flow $3,813 ($497) Cash capital expenditure ($1,241) ($240) Free cash flow $2,572 ($737) • YTD cash generation of $3.8B in operating cash flow and $2.6B of free cash flow • Operating cash flow was adversely impacted vs. prior year due to t

  22. Slide 22: Maintaining Full Year Guidance

    Maintaining Full Year Guidance March 2022 June 2022 Adj. EPS Growth (Constant Fx) FY Guidance FY Guidance Base + 6-8% + 7-9% Healthcare Organic and M&A (5)% (6)% Adjusted EPS LSD Growth LSD Growth • Expecting ~35 million vaccinations in FY22 • Fx rates expected to have a ~1% (~$0.05) negative impact

  23. Slide 23: 4Q: Lapping Strong Year-Ago Quarter and Cycling Through Select Headwinds

    4Q: Lapping Strong Year-Ago Quarter and Cycling Through Select Headwinds 4Q YOY Impact Constant Fx 4Q FY21 Adjusted EPS Growth 28% 4Q 2022 Headwinds Lapping Vaccinations (15)-(17)% Walgreens Health Investments (10)-(12)% Labor Investments (5)% Prior Year One-Time Gains (4)% Total (34)-(38)% FY22 LSD

  24. Slide 24: Long-Term Algorithm with Sustainable Low-Teens EPS Growth

    Long-Term Algorithm with Sustainable Low-Teens EPS Growth Challenges Growth Initiatives • Ongoing reimbursement pressure • Script volume recovery from FY22 operational limitations • Rising inflation and wages • Front of store strength, leveraging: • Consumer sentiment and spending - Digital and omni

  25. Slide 25: Takeaways

    Takeaways • Resilient Core Business • Execution across operating segments • Deep community connections and consumer relevance • Lapping strong year-ago quarter including peak COVID-19 vaccination volumes • Building Our Next Growth Engine: Walgreens Health • New strategic partnership with Buckeye Hea

  26. Slide 26: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  27. Slide 27: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q21 Nine months ended May 31, Change vs. FY21 2022 2021 Amount Percent 2022 2021 Amount Percent Net ear

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q21 Nine months ended May 31, Change vs. FY21 2022 2021 Amount Percent 2022 2021 Amount Percent Adjustm

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended May 31, Change vs. 3Q21 Nine months ended May 31, Change vs. FY21 2022 2021 Amount Percent 2022 2021 Amount Perc

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. During th

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2022 Walgreens Boots United States1 International Walgreens Health Corporate and Other Alliance, Inc. Sales $ 26,695 $ 5,305 $ 5

  33. Slide 33: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2021 Walgreens Boots United States1 International Walgreens Health3 Corporate and Other Alliance, Inc. Sales $ 28,743 $ 5,288 $

  34. Slide 34: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2022 Walgreens Boots United States1 International Walgreens Health Corporate and Other Alliance, Inc. Sales $ 82,394 $ 16,686 $ 1

  35. Slide 35: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2021 Walgreens Boots United States1 International Walgreens Health3 Corporate and Other Alliance, Inc. Sales $ 83,250 $ 14,998 $

  36. Slide 36: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating (loss) income for United States includes equity earnings (loss) in AmerisourceBergen. As a result of the two-month reporting lag, operating (loss) income for

  37. Slide 37: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended May 31, Nine months ended May 31, 2022 2021 2022 2021 Equity earnings (loss) in AmerisourceB

  38. Slide 38: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended May 31, 2022 Three months ended May 31, 2021 (Loss) earnings Income tax Effective tax Earnings before Effect

  39. Slide 39: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended May 31, Nine months ended May 31, 2022 2021 2022 2021 Net cash provided by operating activities (GAAP) $ 1,629 $ 1,754 $

Walgreens Boots Alliance — Q3 2022 Earnings Presentation on 6ix